Home > Quotes > BTX

BioTime, Inc. Stock Quote & Summary Data

BTX 
$4.23
*  
0.04
  negative  
0.95%
Get BTX Alerts
*Delayed - data as of May 22, 2013 
Exchange: AMEX
Industry: Health Care
Community Rating:
View:    BTX After Hours
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

1 Year Target:
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 207,447
Previous Close: $ 4.19
52 Week High /Low: $ 5.0682 / $ 2.67
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. 235,732,744
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year.
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -0.48
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 2.11

 Intraday Chart

5d | 1m | 6m | 12m | More Charting


 Company Description (as filed with the SEC)

We are a biotechnology company focused on the emerging field of regenerative medicine. Our core technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. Products made from these “pluripotent” stem cells are being developed by us and our subsidiaries, each of which concentrates on different medical specialties, including: neuroscience, oncology, orthopedics, and blood and vascular diseases. Our commercial strategy is heavily focused on near-term commercial opportunities including our current line of research products such as PureStem™ cell lines (which we previously called ACTCellerate™ cell line) and associated ESpan™ culture media, HyStem® hydrogels, human embryonic stem cell lines, and royalties from Hextend®.  ... More ...  



News Headlines for BTX

BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair
5/20/2013 9:00:00 AM - Business Wire
BioTime Appoints Franklin Berger to Board of Directors
5/14/2013 7:04:00 PM - Business Wire
ACT, THRX Hit All-time High, NSPH Makes A Big Move, BTX Gets Funding
5/13/2013 10:08:00 PM - RTT News
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist
5/13/2013 9:00:00 AM - Business Wire
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
5/13/2013 7:08:00 AM - Seeking Alpha